These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35426132)

  • 1. The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.
    Wanounou M; Shaul C; Abu Ghosh Z; Alamia S; Caraco Y
    Clin Pharmacol Ther; 2022 Jul; 112(1):156-163. PubMed ID: 35426132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.
    Shaul C; Blotnick S; Adar L; Muszkat M; Bialer M; Caraco Y
    Clin Pharmacokinet; 2022 Aug; 61(8):1187-1198. PubMed ID: 35699912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR; Rettie AE; Brundage RC; Tracy TS
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CYP2C9 Activity in Ethiopian and Non-Ethiopian Jews Using Phenytoin as a Probe.
    Abu Ghosh Z; Alamia S; Shaul C; Caraco Y
    Front Pharmacol; 2020; 11():566842. PubMed ID: 33071782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
    Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.
    Caraco Y; Muszkat M; Wood AJ
    Pharmacogenetics; 2001 Oct; 11(7):587-96. PubMed ID: 11668218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.
    Schwarz UI
    Eur J Clin Invest; 2003 Nov; 33 Suppl 2():23-30. PubMed ID: 14641553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People.
    McDonald MG; Henderson LM; Ray S; Yeung CK; Johnson AL; Kowalski JP; Hanenberg H; Wiek C; Thummel KE; Rettie AE
    J Pharmacol Exp Ther; 2020 Aug; 374(2):233-240. PubMed ID: 32423989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.
    Dai DP; Li CB; Wang SH; Cai J; Geng PW; Zhou YF; Hu GX; Cai JP
    Pharmacogenomics; 2015; 16(13):1475-86. PubMed ID: 26255664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.
    Hernandez W; Aquino-Michaels K; Drozda K; Patel S; Jeong Y; Takahashi H; Cavallari LH; Perera MA
    Transl Res; 2015 Jun; 165(6):651-7. PubMed ID: 25499099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.
    Shaul C; Blotnick S; Muszkat M; Bialer M; Caraco Y
    Mol Diagn Ther; 2017 Feb; 21(1):75-83. PubMed ID: 27878474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
    Lindley KJ; Limdi NA; Cavallari LH; Perera MA; Lenzini P; Johnson JA; Wu AHB; Ridker PM; King CR; Eby CS; Patel S; Shah SV; Beasley TM; Li J; Gage BF
    Clin Pharmacol Ther; 2022 Apr; 111(4):950-955. PubMed ID: 35108398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients.
    Kumar DK; Uppugunduri CRS; Shewade DG; Chandran B V S; Adithan C
    Curr Drug Metab; 2021; 22(12):989-995. PubMed ID: 34802403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.